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Abstract 
Objective. Autonomic dysfunction may contribute to the etiology and exercise intolerance of 
subclinical diabetic heart disease. This study sought the efficacy of exercise training for 
improvement of peak oxygen uptake (VO2peak) and cardiac autonomic function in type 2 
diabetic patients with non-ischemic subclinical left-ventricular (LV) dysfunction. 
Materials/Methods. Forty-nine type 2 diabetic patients with early diastolic tissue Doppler 
velocity >1 standard deviation below the age-based mean entered an exercise intervention 
(n=24) or usual care (n=25) for 6-months (controlled, pre-/post- design). Co-primary 
endpoints were treadmill VO2peak and 5-minute heart-rate variability (by the coefficient of 
variation of normal RR intervals [CVNN]). Autonomic function was additionally assessed by 
resting heart-rate (for sympathovagal balance estimation), baroreflex sensitivity, cardiac 
reflexes, and exercise/recovery heart-rate profiles. Echocardiography was performed for LV 
function (systolic/diastolic tissue velocities, myocardial deformation) and myocardial fibrosis 
(calibrated integrated backscatter). 
Results. VO2peak increased by 11% during the exercise intervention (p=0.001 vs. −1% in 
controls), but CVNN did not change (p=0.23). Reduction of resting heart-rate in the 
intervention group (p<0.05) was associated with an improvement in the secondary endpoint 
of heart-rate variability total spectral power (p<0.05). However, baroreflex sensitivity, 
cardiac reflexes, and exercise/recovery heart-rate profiles showed no significant benefit. No 
effects on LV function were observed despite favorable reduction of calibrated integrated 
backscatter in the intervention group (p<0.05). 
Conclusions. The exercise intolerance of subclinical diabetic heart disease was amenable to 
improvement by exercise training. Despite a reduction in resting heart-rate and potential 
attenuation of myocardial fibrosis, no other cardiac autonomic or LV functional adaptations 
were detected. 
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Abbreviations 
BP  blood pressure 
CVNN  coefficient of variation of normal RR intervals 
E/A ratio ratio of early diastolic (E) and atrial (A) mitral inflow velocities 
E/e’ ratio ratio of early diastolic filling (E) and septal annular (e’) velocities 
Em  early diastolic tissue velocity 
HbA1c  glycated hemoglobin 
LV  left-ventricular 
RRmean  mean RR interval 
SDNN  standard deviation of normal RR intervals 
VO2peak peak exercise oxygen uptake
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Introduction 
Non-ischemic subclinical left-ventricular (LV) dysfunction may be a precursor to heart 
failure in patients with type 2 diabetes [1]. Early intervention to delay or reverse the 
progression of this diabetic cardiomyopathy may improve prognosis, though identifying 
appropriate therapy is difficult in the context of a poorly defined and multifactorial etiology. 
An independent association with cardiac autonomic neuropathy points to distinct autonomic 
involvement [2]; however, the undefined management of this complication limits its potential 
as a pathologic target [3]. Regression of autonomic dysfunction after exercise training has 
been reported in heart disease [4-7], but efficacy in type 2 diabetes remains equivocal [8] – 
largely because of a reliance on uncontrolled cohort studies [9]. These studies have 
nonetheless shown promise in identifying favorable changes in heart-rate variability and 
other markers of cardiac autonomic function [9]. Indeed, autonomic adaptations may be 
independent of concurrent improvements in glycemic control and cardiovascular risk factors 
(by which exercise has a fundamental role in diabetes management) [10-12]. 
Autonomic and LV functional responses to training may be directly related to improvements 
in exercise capacity [13, 14]. Clinically relevant increases in peak oxygen uptake (VO2peak; 
~12%) are typical following exercise interventions in type 2 diabetes [15], though secondary 
changes in LV function may not necessarily be observed [16]. However, prevailing data are 
largely from unselected type 2 diabetic cohorts and the relevance to patients with subclinical 
cardiomyopathy is unclear, particularly in view of exercise intolerance imposed by LV 
dysfunction [13]. Therefore, the primary aim of this controlled, proof-of-concept study – 
performed in type 2 diabetic patients with non-ischemic subclinical LV dysfunction – was to 
evaluate the impact of a 6-month exercise intervention on cardiac autonomic function and 
VO2peak. Heart-rate variability constituted the primary marker of autonomic function, though 
baroreflex sensitivity, conventional cardiac reflex tests and heart-rate profiles during exercise 
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and recovery were also assessed. Echocardiography was performed to determine secondary 
changes in LV structure and function. We hypothesized that an improvement in VO2peak 
would mediate an increase in heart-rate variability, and that these collective benefits would 
promote LV structural and functional adaptations. 
 
Methods 
Patient selection. Asymptomatic patients with type 2 diabetes, aged ≥40 years, were 
screened for subclinical diastolic dysfunction by echocardiography (>1 standard deviation 
below the age-based normal septal early diastolic tissue velocity [Em]) [17] between 
February 2009 and January 2011 (n=225). Exclusion criteria included known cardiovascular 
disease, psychiatric or other severe illness, symptomatic macro- or micro-vascular 
complications of diabetes, low ejection fraction (<50%), valvular disease, or ischemia 
(inducible wall motion abnormalities during exercise stress echocardiography). 
Study design. This controlled trial (Australian New Zealand Clinical Trials Registry number 
ACTRN12609000950268) was designed as a randomized study. However, recruitment 
difficulties secondary to restrictive inclusion criteria and substantive participant burden 
imposed by the intervention dictated observational patient enrolment as part of a non-
randomized, controlled design. Of those with non-ischemic subclinical diastolic dysfunction 
(n=81 after exclusion of two patients with occult coronary artery disease), 24 patients 
amenable to exercise participation were recruited into the 6-month intervention. A separate 
cohort of 25 patients who did not receive the exercise intervention underwent an identical 6-
month follow-up assessment and served as controls [Figure 1]. All patients continued to 
receive standard care from their treating physicians. Co-primary endpoints were VO2peak and 
heart-rate variability (coefficient of variation of normal RR intervals [CVNN]). Study 
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approval was obtained from Princess Alexandra Hospital and University of Queensland 
human research ethics committees and all patients provided written informed consent. 
Clinical and biochemical data. Fasting blood and random urine samples were analysed for 
glucose, glycated hemoglobin (HbA1c), lipids, creatinine, estimated glomerular filtration rate 
and urinary albumin-to-creatinine ratio (for microalbuminuria; defined as ≥3.5 mg/mmol 
[women] or ≥2.5 mg/mmol [men]) by standard hospital pathology laboratory protocols. 
Blood pressure (BP) was recorded in the supine position using an automatic brachial cuff. 
Carotid-femoral pulse wave velocity was recorded by applanation tonometry to determine 
aortic stiffness. 
Exercise intervention. Individualized aerobic/resistance training programs were based on 
weekly exercise volumes recommended for type 2 diabetes (i.e. ≥150 minutes of moderate 
intensity or ≥90 minutes of vigorous intensity exercise) [10]. The intervention was 
administered by an accredited exercise physiologist via gym sessions (up to 75 minutes twice 
weekly, comprising 20-40 minutes of aerobic exercise and 6-12 resistance exercises) and 
home-based prescription. Target exercise intensity (moderate-vigorous) was primarily 
controlled using rating of perceived exertion, with intermittent verification by heart rate 
monitors. Subjects identifying facility access as a barrier to ongoing participation were 
offered substitute home-based exercise programs with telephone support and “refresher” gym 
sessions as an alternative to study withdrawal. A validated physical activity questionnaire 
determined adherence with the exercise prescription [16]. 
Exercise testing. Patients performed maximal treadmill testing according to the Bruce 
protocol. Expired gas analysis for VO2peak (applying 20-second interval data averaging) was 
measured using a standard commercial system (Vmax, SensorMedics, Yorba Linda, CA). 
The chronotropic index was quantified by heart-rate reserve (peak – resting heart-rate) as a 
percentage of age-predicted heart-rate reserve (220 – age – resting heart-rate) [18]. Post-
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exercise heart-rate recovery at 1-minute [18] and estimated maximum metabolic equivalents 
according to a standard formula for walking [19] were also recorded. Post-stress 
echocardiography was performed to exclude ischemia (i.e. inducible wall motion 
abnormalities). 
Cardiac autonomic function testing. Patients were assessed in a quiet, temperate room 
following ≥15 minutes supine rest and instructed to relax, remain awake, and refrain from 
talking/moving. They were also asked to abstain from smoking and caffeine (12 hours), and 
alcohol, heavy exercise and antihypertensive medications (24 hours), as previously described 
[2, 18]. Heart-rate variability and baroreflex sensitivity were derived from 5-minute 
recordings of ECG (3-lead) and central (ascending aortic) BP. The latter was measured by 
continuous radial applanation tonometry (Colin CBM-7000; Colin Corp, Komaki-city, 
Japan), with generation of the central waveform using a validated transfer function [20] and 
commercial software (SphygomoCor; AtCor Medical, Sydney, Australia). ECG and central 
BP were digitized using a Powerlab 8SP data acquisition system (AD Instruments, Sydney, 
Australia) and stored for offline analysis using LabChart software (AD Instruments). RR 
intervals and beat-to-beat central systolic BPs were detected automatically and visually 
verified. Ectopic beats, in addition to intervals >20% different to their preceding interval, 
were interpolated [21]. Data were excluded when the interpolation rate exceeded 10%. Poor 
quality tonometry was responsible for missing baroreflex sensitivity data in 4 control- and 5 
intervention-group patients, though heart-rate variability was still analysed in this cohort. 
Heart-rate variability parameters were calculated as previously described [22]. These 
included absolute time domain (CVNN [primary endpoint], standard deviation of normal RR 
intervals [SDNN], and root-mean-square of differences in successive RR intervals) and 
frequency domain parameters (total power of heart-rate variability and its components within 
low- and high-frequency bands, normalized low-frequency power [i.e. low-frequency power 
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relative to the sum of low- and high-frequency power], and the ratio of low-/high-frequency 
power). Resting heart-rate and its reciprocal (mean RR interval [RRmean]) as well as the ratio 
of low-/high-frequency power, represent indirect markers of cardiac sympathovagal balance. 
However, resting heart-rate was prioritised  for this purpose due to superior reliability [22].  
Baroreflex sensitivity was calculated by the time domain cross-correlation method, which 
quantifies the linear RR/systolic BP regression coefficient at a baroreflex delay 
corresponding to the maximal correlation [23].  
Cardiac reflex tests were performed and analysed according to standard protocols [24] and 
included deep breathing (for the maximal expiration/inspiration ratio), Valsalva manoeuvre 
(for the Valsalva ratio) and orthostasis (for the standing 30:15 ratio and 1-minute change in 
systolic BP). Cardiac reflex tests provided the basis for cardiac autonomic neuropathy 
classification in 47 patients (data was incomplete for 1 control- and 1 intervention-group 
patient). Neuropathy was defined by ≥1 abnormal cardiac reflex test [3] according to age-
based normative data [24].  
LV structure and function. Conventional and color tissue Doppler apical views were 
acquired using a Vivid 7 ultrasound machine (GE Medical, Horten, Norway) and analysed 
offline using commercial software (Echopac PC, GE Medical). LV mass (indexed to body 
surface area) was determined from 2-D targeted M-mode echocardiography and calculated 
according to Devereux’s formula [25]. Ejection fraction was measured using a modified 
Simpson’s biplane method. Calibrated integrated backscatter (a marker of signal intensity that 
correlates with myocardial fibrosis on biopsy [26]) was calculated from the mean of posterior 
wall and anteroseptal IB intensities (quantified in the parasternal long axis view) following 
subtraction of these values by the mean pericardial IB intensity at end-diastole [27]. Pulsed-
wave Doppler echocardiography characterized the peak early (E) and atrial (A) mitral inflow 
velocities (i.e. for the E/A ratio), and the E wave deceleration time. LV filling pressure was 
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estimated by the ratio of peak early diastolic filling (E) and septal annular (e’) velocities 
(E/e’). Color tissue Doppler peak myocardial systolic tissue velocity and Em were averaged 
in 6 basal LV segments. Strain (percent LV segment deformation) and strain rate (rate of 
deformation) were also derived from tissue Doppler, as previously described [27]. Offline 
analysis of images at baseline and 6-month follow-up were performed by the same observer. 
Statistical methods. In the absence of a consensus change (∆) in CVNN constituting clinical 
relevance, we previously reported that 21 patients per group would be required to detect a 
difference equivalent to 30% of between-subject standard deviation [22]. This sample would 
also enable detection of a clinically relevant 10% increase in VO2peak based on its test-retest 
coefficient of variation (~5%) [28].  Thus, initial group sizes accommodated ~15% 
withdrawal during the study.  
An intention-to-treat approach to the data analysis was applied. Superiority of intervention vs. 
control was determined by a significant group × time interaction in a linear mixed-effects 
model with a random intercept and age, sex, group, and time as fixed effects. Additional 
time-varying covariates were included in the model where appropriate. Post-hoc assessments 
of within-group change over time were based on the estimated marginal means (presented 
with standard error and 95% confidence interval). Normality of distribution was assessed by 
the Kolmogorov-Smirnov test. Skewed autonomic functional parameters were natural log 
transformed. Baseline clinical data expressed as mean ± standard deviation, median 
(interquartile range), or n (%), were compared using independent t, Mann Witney U, or 2 
tests, respectively. Linear associations were assessed by Pearson or Spearman rank 
correlation coefficients, where appropriate. Multiple linear regression modelling was 
performed using the backward method. Data were analysed using SPSS Statistics version 
19.0 (SPSS, Inc., Chicago, Illinois). Statistical significance was defined by p<0.05. 
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Results 
Clinical characteristics displayed in [Table 1] and [Table 2] revealed that groups were similar 
at baseline except for the higher BP of patients allocated to exercise training. Follow-up data 
were analysed in all patients except for two in the intervention group (one withdrew for an 
unspecified reason and the other was excluded due to having undergone bariatric surgery). 
Additional missing data for primary endpoints included heart-rate variability in one control 
and one intervention group patient (frequent ectopy dictated interpolation of >10% of RR 
intervals) and VO2peak in a further three patients (two controls and one from the intervention 
group) due to technically inadequate expired gas measurements. Estimated metabolic 
equivalents for the latter patients were still analysed. 
Of patients in the intervention group who completed the study (n=22), two had earlier 
withdrawn from exercise training altogether (citing loss of interest and lack of time) and five 
had ceased the gym-based component in favor of an exclusive home-based program. 
Nonetheless, 95% of patients in the intervention reported exercise volumes that met or 
exceeded guidelines, which was significantly more than in the control group (64%; p=0.013). 
Analyses of specific modes of physical activity revealed no difference between groups in 
time spent walking (p=0.87) or doing moderate intensity activities (p=0.81). However, the 
intervention group reported significantly more vigorous activity time than controls (p<0.001), 
which translated to greater total activity time (p=0.004). 
Changes in clinical characteristics [Table 2]. A reduction in waist circumference (but not 
body mass), and a borderline significant lowering of mean arterial pressure were observed in 
the intervention group. Within-group changes pointed to additional benefits for systolic BP 
and HDL cholesterol, but these were not significant relative to changes in the control group. 
BP reduction did not extend to changes in aortic stiffness. There was no relative improvement 
in diabetes control or other lipids. However, there was a tendency for a greater proportion of 
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exercise-trained patients to report reductions in hypoglycemic medication dose during the 
study period (i.e. 14% reported an increase / 18% a decrease vs. 20% / 4% for controls). This 
predominantly reflected insulin dose reductions in the intervention group (14% vs. 4%, 
controls). Changes in other medications were observed, but less commonly and to a similar 
extent between groups. These included antihypertensive medications (5% reported an 
increase / 5% a decrease in the intervention group vs. 0% / 8% in controls), statins (5% 
increase / 0% decrease, intervention group vs. 4% increase / 0% decrease, controls) and 
antidepressants (0% increase / 5% decrease [serotonin-norepinephrine reuptake inhibitor], 
intervention group vs. 4% increase [tricyclic antidepressant] / 0% decrease, controls). 
Primary endpoints [Figure 2]. Exercise capacity (VO2peak) and heart-rate variability 
(CVNN) were similar in control and intervention groups at baseline. The exercise 
intervention elicited a significant 11% increase in VO2peak compared with –1% in controls 
(+3.0 mL kg
-1
 min
-1
 vs. controls, 95% confidence interval [1.4 to 4.6]). Estimated metabolic 
equivalents pointed to an even greater magnitude improvement (+29% vs. +2% in controls; 
Table 2). Enhanced exercise capacity was not accompanied by an improvement in CVNN 
(+0.12 ln [%] vs. controls, 95% confidence interval [–0.08 to 0.33]), though the within-group 
increase in the intervention group was borderline significant (p=0.073). Re-analysis 
following additional adjustment for mean arterial pressure (owing to the group difference in 
BP at baseline) did not affect these findings (data not shown).  
Secondary endpoints of cardiac autonomic function [Table 3]. Of the wider battery of 
autonomic function tests, only the high-frequency power of heart-rate variability was 
significantly different between groups at baseline (lower in the intervention group; p=0.039). 
Markers of cardiac sympathovagal balance. Exercise training induced a significant decrease 
in resting heart-rate and a corresponding increase in its reciprocal (RRmean). No changes in the 
low-/high-frequency ratio were observed. 
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Heart-rate variability and baroreflex sensitivity. In contrast to CVNN, alternate markers of 
global heart-rate variability (SDNN and total spectral power) increased in the intervention 
group, with the change in total spectral power being significant relative to controls. Of 
specific heart-rate variability components, absolute (but not normalized) low-frequency 
power tended to improve in the intervention group (p=0.093), but neither the root-mean-
square of differences in successive RR intervals, nor high-frequency power, benefited from 
the intervention. Baroreflex sensitivity remained unchanged in both groups. 
Cardiac reflex tests. Deep breathing, Valsalva and orthostatic tests did not change in either 
group during the study.  
Heart-rate profile during exercise and recovery. There was a trend toward improvement of 
the chronotropic index with exercise training (p=0.066), but no effects on heart-rate recovery 
were identified. 
Determinants of change in CVNN. No associations of ∆CVNN with its co-primary 
endpoint (∆VO2peak) were observed, though its univariate correlates included baseline CVNN 
(r=–0.35, p=0.018), ∆RRmean (r=0.38, p=0.011) and baseline estimated glomerular filtration 
rate (r=0.32, p=0.034). These variables were separately entered into multiple linear regression 
models alongside variables considered clinically relevant (age, sex, ∆VO2peak, ∆HbA1c, and 
baseline CVNN). Independent correlates of ∆CVNN included lower baseline CVNN (β=–
0.40, p=0.008; adj. R
2=0.18, p=0.008) and greater ∆RRmean (β=0.30, p=0.049; adj. R
2
=0.19, 
p=0.007).  
Secondary endpoints of LV structure and function [Table 4]. Echocardiography data were 
similar between groups at baseline except for higher E/A ratio in the intervention group 
(p=0.043). Ejection fraction and LV mass remained unchanged in both groups during the 
study. The sole parameter to improve with intervention was calibrated integrated backscatter. 
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Diastolic function. Em increased significantly and to a similar extent in both groups, resulting 
in no net benefit from the intervention. Of the more load-dependent parameters (adjusted for 
mean arterial pressure), there was a significant increase in the E/A ratio in controls. Notably, 
this was discordant with changes in LV filling pressure (E/e’ ratio), which increased in the 
intervention group (albeit to a similar extent compared with controls). 
Systolic function. The exercise intervention resulted in no favorable adaptations of systolic 
tissue velocity, strain, or strain rate, though the latter two variables increased in parallel in 
both groups during the study. 
 
Discussion 
In this controlled trial, a 6-month exercise intervention elicited a significant and clinically 
relevant improvement in exercise capacity (VO2peak) in type 2 diabetic patients with 
subclinical LV dysfunction. However, concomitant autonomic adaptations were absent on the 
basis of the primary measurement of heart-rate variability (CVNN) and reinforced by no 
changes in baroreflex sensitivity, heart-rate profiles during exercise and recovery, or cardiac 
reflex tests. The potential for a mechanism of benefit in relation to cardiac autonomic 
function should not altogether be excluded on the basis of a significant gain in total spectral 
power. The within-group change in CVNN after exercise training was also borderline 
significant. Together, these more positive findings from heart-rate variability may have been 
related to a favorable shift in cardiac sympathovagal balance (estimated by resting heart-rate), 
which was independently associated with ∆CVNN. Despite potential anti-fibrotic effects of 
exercise training (based on calibrated integrated backscatter), there were no secondary 
benefits for LV systolic or diastolic function.  
Exercise capacity. Although improvements in exercise capacity of ~12% may be expected 
with exercise training in unselected patients with type 2 diabetes [15], this is the first study to 
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demonstrate similar efficacy in the context of subclinical LV dysfunction, which is a 
recognized portent of exercise intolerance in both type 2 diabetes [13, 29] and non-diabetic 
populations [30]. Since the observed increment in VO2peak may confer an ~20% reduction in 
mortality risk [31, 32], exercise may be applied as a therapeutic intervention to improve 
prognosis in the one-third of apparently healthy type 2 diabetic patients typically afflicted by 
this complication [33]. The findings reinforce the application of exercise as therapy for 
patients with type 2 diabetes based on well-established efficacy for improvement of glycemic 
control [12], cardiovascular risk factors, and vascular function [10, 11]. 
Exercise training and cardiac autonomic function. Notwithstanding its prognostic 
importance, there is a dearth of treatment strategies for the autonomic dysfunction of type 2 
diabetes [3], though reduced incidence and progression may be achieved by composite 
reduction of hyperglycemia [34] and cardiovascular risk [35]. For these purposes, lifestyle 
modification has recognized efficacy; however, the current 6-month exercise intervention 
failed to mediate regression of the primary endpoint of heart-rate variability (CVNN; a 
marker of parasympathetic function). Although CVNN indicated no effect, there was 
heterogeneity in responses of the wider battery of heart-rate variability indices (i.e. relative 
improvement in total spectral power, but not CVNN, SDNN, root-mean-square of differences 
in successive RR intervals, or low- or high-frequency power). CVNN was of most interest 
given superior sensitivity [36] and reproducibility [22] in diabetic patients and relative 
independence of resting heart-rate (by virtue of its definition as SDNN relative to RRmean). 
The importance of this latter characteristic was highlighted by the present finding of RRmean 
lengthening (i.e. reduction of resting heart-rate) as an independent correlate of changes in 
CVNN and other heart-rate variability parameters (only data for CVNN is shown). This 
implicates the relative bradycardia induced by exercise training as responsible for significant 
within- and between-group changes in variables with a recognized relation to heart-rate (i.e. 
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SDNN and total spectral power) [37]. Findings based on these heart-rate variability markers 
are consistent with evidence in healthy individuals [38] and uncontrolled cohort studies of 
patients with type 2 diabetes [9], which mostly support that the benefits of exercise training 
extend to an increase in heart-rate variability (i.e. beyond well-known improvements in 
cardiometabolic risk factors). 
Regardless of whether an exercise-training-mediated relative bradycardia is responsible for 
concurrent changes in heart-rate variability, the clinical relevance of a reduction in the resting 
heart-rate must itself be recognised since higher resting heart-rate predicts adverse outcome 
[39]. In the current study, the resting heart-rate was interpreted as an estimate of cardiac 
sympathovagal balance. This was because – aside from the intrinsic sinus depolarising rate, 
resting heart-rate is a product of the tonic sympathetic vs. parasympathetic input [40][41]. 
Although inter-individual variation in the intrinsic rate introduces ambiguity to cardiac 
sympathovagal balance estimation from a single point estimate of resting heart-rate, changes 
over time may reflect alteration of this balance when stability of the intrinsic rate can be 
assumed. Of factors known to influence the intrinsic rate, the greatest threat to this 
assumption in the current study may have come from exercise training-mediated intrinsic 
electrophysiological adaptations [42]. However, since these are typically observed in highly-
trained endurance athletes [42, 43], incidence in this relatively short-term intervention study 
is improbable. We therefore interpret the reduction of resting heart-rate to be of autonomic 
origin and to reflect a favorable shift in cardiac sympathovagal balance (i.e. an increase in 
parasympathetic tone, a reduction in sympathetic tone, or a combination of the two). It is 
acknowledged that this is discordant with the lack of a treatment effect on the low-/high-
frequency ratio, which is purported have a similar physiological basis. This may be explained 
by our measurement of heart-rate variability solely from supine ECG recordings since 
patients with type 2 diabetes have previously shown training-induced improvements in the 
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low-/high-frequency ratio only upon measurement in the standing position (i.e. during 
sympathetic activation) [44]. In any case, because the origins and significance of the low-
/high-frequency ratio remain disputed [45, 46] and its reproducibility is relatively poor [22], 
we support that conclusions about exercise training effects on cardiac sympathovagal balance 
in this study be interpreted as positive (i.e. based on resting heart-rate data).  
Although we observed positive effects on some heart-rate variability and cardiac 
sympathovagal balance parameters, this did not extend to baroreflex sensitivity. This is in 
contrast to a trial in unselected type 2 diabetic patients, in which baroreflex sensitivity, but 
not heart-rate variability, was shown to improve following exercise training [8]. We also 
found heart-rate recovery to remain unchanged with exercise training, which was surprising 
given its strong association with exercise capacity [13] and capacity to improve following 
cardiac rehabilitation [47]. This result is consistent with a lack of change in parasympathetic 
function [18]. The chronotropic index has well-established origins in autonomic function and 
demonstrated a trend toward improvement, although the precise mechanistic basis for this 
change is unclear. 
Exercise training and LV structure / function. Improved calibrated integrated backscatter 
in the current study points to a favorable reduction of myocardial fibrosis and/or other 
structural adaptation following exercise training. Similar changes have been reported with 
lifestyle modification-induced weight loss in obese patients [48]. However, in contrast to this 
previous work, we did not observe coincident LV functional improvements. Although a 
previous study from our institution in unselected patients with type 2 diabetes demonstrated 
that Em, systolic tissue velocity, strain and strain rate were unresponsive to lifestyle 
modification (which included an exercise component) over 12 months [16] and 36 months 
[14], increases in tissue velocities in patients with worse function at baseline pointed to 
exercise being efficacious in patients with subclinical LV dysfunction [16]. In this context, 
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these negative findings were surprising. The study was not powered for LV functional 
endpoints, so the possibility of an inadequate sample size should be considered, particularly 
since the magnitude change in Em in the intervention group (1.1 cm/s) was clinically relevant 
and equivalent to that which may be expected with intensive pharmacologic therapy [49]. The 
basis of the significant increase in E/A ratio in controls is unclear since this marker is load-
dependent and non-linear.  
Study limitations. Although clinical data indicated that groups were relatively similar at 
baseline and robust statistical strategies were employed to account for group differences, it is 
acknowledged that a randomised study is necessary to preclude unknown confounding 
imbalances and selection bias. The study also lacked blinding, although this is a common 
feature of exercise trials. Changes in medications may have confounded treatment effects on 
some of the study endpoints. In addition, although patients in the control group performed 
significantly less physical activity than those in the intervention, larger effect sizes may have 
been observed if comparisons had been made against completely sedentary controls. 
The lack of significant improvement in HbA1c represents an appealing culprit for some of the 
negative findings. However, this should not be interpreted as a failure to enhance the 
metabolic milieu because more patients in the intervention group reported reductions in 
hypoglycemic medication dose during the study. More sensitive markers of glycemic control 
and insulin sensitivity may have detected changes. 
In view of the borderline significant within-group improvement of CVNN after exercise 
training, the prospect of inadequate statistical power for this co-primary endpoint must be 
considered. The present sample size was based on an expected improvement of 30% of the 
between-subject standard deviation [22], which exceeded the observed change. The latter 
may constitute a clinically relevant effect that we were underpowered to detect. However, it 
is equally possible that our short-term reproducibility study [22] under-estimated 6-month 
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stability of CVNN, particularly in view of incident changes in clinical status and therapy 
during the trial. In turn, it was noteworthy that the lack of between-group differences in LV 
functional parameters originated from parallel improvements in both intervention and control 
groups. The culprit factors driving collective migration of Em, strain and strain rate toward 
more favorable values may relate to patient selection and tendencies for regression to the 
population mean. The same phenomenon may also have confounded analyses of autonomic 
endpoints in view of the tendency for lower baseline values in the intervention group and 
linear regression demonstrating inverse associations of change in CVNN with baseline 
CVNN.  
Conclusions. The results of this study indicate that improvements in exercise capacity are 
attainable in type 2 diabetic patients with subclinical LV dysfunction. Exercise training may 
therefore significantly improve prognosis in this sub-population at elevated cardiovascular 
risk. Although this did not translate to adaptations of cardiac autonomic function based on the 
primary endpoint of heart-rate variability (CVNN), we observed a potential favorable shift in 
cardiac sympathovagal balance. These mixed findings in relation to cardiac autonomic 
function are similar to outcomes from previously trialled monotherapies. Although they do 
not question the key role of exercise training in type 2 diabetes management, the results may 
indicate that a multifactorial approach (inclusive of exercise training) is needed. Whether 
autonomic dysfunction represents a suitable pathophysiological target for the treatment of 
non-ischemic diabetic cardiomyopathy remains unclear. Indeed, the lack of improvement in 
LV function (notwithstanding attenuation of myocardial fibrosis) may have stemmed from 
inadequate cardiac autonomic effects. Future studies of exercise training in this setting may 
consider a longer or more intensive treatment period and/or the use of co-interventions.  
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Table 1. Baseline clinical characteristics by group assignment 
 Control 
(n=25) 
Exercise 
(n=24) 
P
 a
 
Clinical parameters    
Age (years) 60  9 59  10 0.72 
Male 10 (40) 13 (54) 0.32 
Duration of diabetes (years) 6 (4 – 11) 8 (5 – 13) 0.32 
Previous/current smoker 10 (40) 8 (33) 0.63 
Body mass index (kg/m
2
) 32  5 32  6 0.93 
Systolic blood pressure (mm Hg) 123  15 131  15 0.081 
Diastolic blood pressure (mm Hg) 70  6 76  7 0.004 
Cardiac autonomic neuropathy 3 (13) 7 (30) 0.13 
1 abnormal cardiac reflex test 1 (4) 4 (17) 0.14 
2 abnormal cardiac reflex tests 2 (8) 3 (13) 0.60 
Orthostatic hypotension 0 0 – 
Biochemistry    
Fasting glucose (mmol/l) 8.73  3.23 8.28  3.10 0.63 
HbA1c (%) 7.69  1.71 7.68  1.61 0.98 
Total cholesterol (mmol/l) 4.77  0.96 4.63  1.04 0.62 
LDL cholesterol (mmol/l) 2.82  0.86 2.85  1.03 0.91 
HDL cholesterol (mmol/l) 1.13  0.30 1.03  0.27 0.22 
Triglycerides (mmol/l) 1.50 (1.25 – 1.90) 1.20 (0.90 – 1.85) 0.13 
eGFR (mL/min) 85.5  18.2 85.7  22.0 0.97 
Creatinine (mol/l) 71.0  13.8 75.9  21.6 0.35 
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 Control 
(n=25) 
Exercise 
(n=24) 
P
 a
 
Urea (mmol/l) 5.07  1.23 5.24  1.75 0.70 
Microalbuminuria 7 (28) 5 (21) 0.56 
Treatment    
Diet/exercise only 4 (16) 2 (8) 0.41 
Metformin 19 (76) 19 (79) 0.79 
Insulin 5 (20) 7 (29) 0.46 
Sulfonylureas 5 (20) 10 (42) 0.10 
Angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker 
14 (56) 14 (58) 0.87 
β-blockers 0 (0) 1 (4) 0.30 
Calcium channel blockers 3 (12) 3 (13) 0.96 
Statins 12 (48) 12 (50) 0.89 
Aspirin 7 (28) 9 (38) 0.48 
Serotonin-specific reuptake inhibitor 3 (12) 1 (4) 0.32 
Serotonin-norepinephrine reuptake 
inhibitors 
3 (12) 4 (17) 0.64 
Data are mean  standard deviation, median (interquartile range), or n (%). 
a
 P values refer to group comparisons by independent t, Mann Witney U, or 2 tests, where 
appropriate. 
eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
 
Table 2. Anthropometric, biochemical and clinical data 
Variable Group 
Baseline 
mean (SE) 
6-months 
mean (SE) 
Change from baseline 
mean (95% CI) 
P 
a
 
Body mass (kg) Control 88.7 (3.3) 88.4 (3.3) –0.4 (–1.7 to 1.0)  
Exercise 92.8 (3.4) 92.2 (3.4) –0.6 (–2.0 to 0.8) 0.83 
Waist (cm) Control 106.1 (2.7) 106.9 (2.7)  0.8 (–0.7 to 2.3)  
Exercise 107.3 (2.7) 105.5 (2.7) –1.9 (–3.5 to –0.2)* 0.021 
HbA1c (%) Control 7.69 (0.31) 7.64 (0.31) –0.05 (–0.29 to 0.20)  
Exercise 7.68 (0.32) 7.58 (0.32) –0.09 (–0.36 to 0.17) 0.80 
LDL cholesterol 
(mmol/L) 
Control 2.78 (0.19) 2.50 (0.19) –0.3 (–0.7 to 0.1)  
Exercise 2.83 (0.19) 2.73 (0.19) –0.1 (–0.5 to 0.3) 0.49 
HDL cholesterol 
(mmol/L) 
Control 1.11 (0.05) 1.12 (0.05)  0.01 (–0.06 to 0.08)  
Exercise 1.04 (0.05) 1.12 (0.06)  0.09 (0.01 to 0.16)
*
 0.14 
Systolic BP 
(mm Hg) 
Control 122 (3) 122 (3)  0 (–3 to 3)  
Exercise 131 (3) 127 (3) –4 (–7 to 0)* 0.12 
Diastolic BP 
(mm Hg) 
Control 70 (1) 71 (1)  1 (–1 to 3)  
Exercise 76 (1) 74 (1) –2 (–4 to 1) 0.12 
Mean arterial 
pressure (mm Hg) 
Control 87 (2) 88 (2)  1 (–2 to 3)  
Exercise 94 (2) 92 (2) –2 (–5 to 0) 0.083 
Aortic pulse wave 
velocity (m/s) 
b
 
Control 9.5 (0.4) 9.6 (0.4)  0.1 (–0.2 to 0.4)  
Exercise 10.3 (0.4) 10.3 (0.4)  0 (–0.4 to 0.3) 0.60 
Metabolic 
equivalents 
Control 9.8 (0.5) 10.0 (0.5)  0.2 (–0.4 to 0.8)  
Exercise 9.4 (0.5) 12.0 (0.5)  2.7 (2.0 to 3.3)
‡
 <0.001 
Data are expressed as estimated marginal means (following adjustment for age and sex) with 
standard error or 95% confidence intervals. 
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a
 P values refer to between-group comparisons of change (group × time interaction) in a 
linear mixed-effects model with a random intercept and age, sex, group, and time as fixed 
effects. 
b 
Aortic pulse wave velocity reflects additional adjustment for mean arterial pressure. 
*
p<0.05 and 
‡
p<0.001 indicate a significant within-group change from baseline. 
BP, blood pressure; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; SE, standard error.
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Table 3. Secondary endpoints of cardiac autonomic function 
Variable Group 
Baseline 
mean (SE) 
6-months 
mean (SE) 
Change from baseline 
mean (95% CI) 
P 
a
 
Resting heart-rate 
(beats/min) 
Control 69 (2) 70 (2)  1 (–2 to 3)  
Exercise 73 (2) 69 (2) –3 (–6 to –1)* 0.022 
RRmean (ms) Control 875 (18) 863 (18) –12 (–39 to 15)  
Exercise 839 (19) 877 (19)  39 (10 to 67)
*
 0.013 
Heart-rate variability 
SDNN (ln ms) Control 3.40 (0.10) 3.40 (0.10)  0 (–0.16 to 0.15)  
Exercise 3.18 (0.10) 3.35 (0.11)  0.17 (0.01 to 0.33)
*
 0.12 
RMSSD (ln ms) Control 2.91 (0.11) 2.96 (0.11)  0.05 (–0.12 to 0.22)  
Exercise 2.61 (0.11) 2.76 (0.12)  0.15 (–0.03 to 0.33) 0.42 
Total spectral 
power (ln ms
2
) 
Control 6.78 (0.20) 6.76 (0.20) –0.02 (–0.34 to 0.30)  
Exercise 6.24 (0.20) 6.74 (0.21)  0.50 (0.16 to 0.84)
†
 0.032 
Low-frequency 
power (ln ms
2
) 
Control 5.34 (0.25) 5.25 (0.25) –0.08 (–0.49 to 0.32)  
Exercise 4.78 (0.25) 5.20 (0.26)  0.42 (–0.01 to 0.86) 0.093 
High-frequency 
power (ln ms
2
) 
Control 4.96 (0.22) 5.03 (0.22)  0.07 (–0.27 to 0.41)  
Exercise 4.30 (0.22) 4.53 (0.23)  0.24 (–0.12 to 0.59) 0.50 
Low-frequency 
power normalized (%) 
Control 58.1 (3.8) 55.9 (3.8) –2.2 (–9.3 to 5.0)  
Exercise 60.0 (3.8) 64.6 (4.0)  4.6 (–2.9 to 12.2) 0.20 
Low-/high- 
frequency ratio (ln) 
Control 0.38 (0.19) 0.23 (0.19) –0.15 (–0.49 to 0.19)  
Exercise 0.53 (0.19) 0.69 (0.20)  0.17 (–0.19 to 0.53) 0.20 
Baroreflex sensitivity 
(ms/mm Hg) 
b
 
Control 7.02 (0.75) 7.94 (0.74)  0.92 (–0.44 to 2.28)  
Exercise 6.08 (0.78) 6.45 (0.76)  0.36 (–1.11 to 1.83) 0.58 
Cardiac reflex tests 
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Variable Group 
Baseline 
mean (SE) 
6-months 
mean (SE) 
Change from baseline 
mean (95% CI) 
P 
a
 
Deep breathing E/I 
ratio (ln) 
Control 0.24 (0.02) 0.24 (0.02)  0.01 (–0.03 to 0.04)  
Exercise 0.18 (0.02) 0.21 (0.02)  0.02 (–0.01 to 0.06) 0.46 
Valsalva ratio (ln) Control 0.46 (0.03) 0.43 (0.03) –0.03 (–0.09 to 0.02)  
Exercise 0.39 (0.03) 0.36 (0.03) –0.03 (–0.08 to 0.03) 0.90 
Standing 30:15 
ratio (ln) 
Control 0.17 (0.02) 0.20 (0.02)  0.04 (–0.01 to 0.08)  
Exercise 0.17 (0.03) 0.21 (0.03)  0.04 (–0.01 to 0.08) 0.96 
Standing ∆ systolic 
BP 1 minute (mm Hg) 
Control 4 (2) 2 (2) –2 (–6 to 3)  
Exercise 0 (2) 3 (2)  3 (–2 to 8) 0.14 
Heart-rate profile during exercise and recovery 
Chronotropic index 
(%) 
Control 94 (3) 92 (3) –1 (–6 to 3)  
Exercise 93 (3) 97 (3)  5 (0 to 9) 0.066 
Heart-rate recovery 
1 minute (beats/min) 
Control 28 (2) 27 (2) –1 (–4 to 2)  
Exercise 25 (2) 26 (2)  1 (–2 to 4) 0.41 
Data are expressed as estimated marginal means (following adjustment for age and sex) with 
standard error or 95% confidence intervals. 
a
 P values refer to between-group comparisons of change (group × time interaction) in a 
linear mixed-effects model with a random intercept and age, sex, group, and time as fixed 
effects. 
b 
Baroreflex sensitivity reflects additional adjustment for systolic blood pressure. 
*
p<0.05 and 
†
p<0.01 indicate a significant within-group change from baseline. 
∆, change; BP, blood pressure; CI, confidence interval; E/I ratio, expiration/inspiration heart-
rate ratio; RRmean, mean RR interval; RMSSD, root mean square of differences in successive 
RR intervals; SDNN, standard deviation of normal RR intervals; SE, standard error.
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Table 4. Myocardial structure and function 
Variable Group 
Baseline 
mean (SE) 
6-months 
mean (SE) 
Change from baseline 
mean (95% CI) 
P 
a
 
Ejection fraction (%) Control 65 (1) 64 (1) –1 (–4 to 2)  
Exercise 62 (1) 59 (1) –2 (–5 to 0) 0.44 
LV mass index (g/m
2
) Control 78 (4) 82 (4)  3 (–4 to 11)  
Exercise 79 (5) 86 (5)  7 (–1 to 16) 0.50 
Calibrated integrated 
backscatter (dB) 
Control –16.7 (0.9) –17.9 (0.9) –1.3 (–3.4 to 0.9)  
Exercise –16.2 (1.0) –20.7 (1.0) –4.4 (–6.7 to –2.2)‡ 0.049 
Diastolic function 
Em (cm/s) Control 5.0 (0.2) 5.8 (0.2)  0.8 (0.4 to 1.2)
†
  
 Exercise 4.7 (0.2) 5.8 (0.2)  1.1 (0.6 to 1.5)
‡
 0.34 
E/A ratio 
b
 Control 0.77 (0.04) 0.96 (0.04)  0.19 (0.12 to 0.26)
‡
  
Exercise 0.89 (0.04) 0.94 (0.04)  0.06 (–0.02 to 0.13) 0.016 
Deceleration time 
(ms) 
b
 
Control 232 (11) 227 (11) –6 (–25 to 14)  
Exercise 232 (11) 213 (11) –19 (–40 to 2) 0.34 
E/e’ ratio b Control 11.8 (0.8) 13.4 (0.8)  1.6 (–0.2 to 3.3)  
Exercise 13.4 (0.8) 15.9 (0.8)  2.5 (0.6 to 4.4)
*
 0.46 
Systolic function      
Systolic tissue 
velocity (cm/s) 
Control 5.8 (0.2) 6.1 (0.2)  0.3 (–0.1 to 0.7)  
Exercise 5.3 (0.2) 5.7 (0.2)  0.3 (–0.1 to 0.8) 0.90 
Strain (%) Control 21.0 (0.7) 25.8 (0.7)  4.8 (3.2 to 6.3)
‡
  
Exercise 20.8 (0.7) 25.1 (0.7)  4.3 (2.7 to 5.8)
‡
 0.65 
Strain rate (s
-1
) Control 1.4 (0.1) 1.7 (0.1)  0.3 (0.2 to 0.4)
‡
  
Exercise 1.3 (0.1) 1.6 (0.1)  0.4 (0.2 to 0.5)
‡
 0.52 
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Data are expressed as estimated marginal means (following adjustment for age and sex) with 
standard error or 95% confidence intervals. 
a
 P values refer to between-group comparisons of change (group × time interaction) in a 
linear mixed-effects model with a random intercept and age, sex, group, and time as fixed 
effects. 
b
 Variables reflect additional adjustment for mean arterial pressure. 
*
p<0.05, 
†
p<0.01, and 
‡
p<0.001 indicate a significant within-group change from baseline. 
CI, confidence interval; E/A ratio, ratio of early diastolic (E) and atrial (A) mitral inflow 
velocities; E/e’; ratio of early diastolic filling (E) and septal annular (e’) velocities; Em, early 
diastolic tissue velocity; LV, left-ventricular; SE, standard error.
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Figure legends 
Figure 1: Flow diagram of patient participation in the study 
CAD, coronary artery disease; LV, left-ventricular. 
 
Figure 2: Baseline, follow-up, and change in primary endpoints. 
A: Baseline and 6-month data for VO2peak. 
Data are age- and sex-adjusted estimated marginal means with standard error (error bars). P 
values reflect the within-group change over time (paired; baseline vs. 6-months).  
B: Change in VO2peak from baseline. 
Data are age- and sex-adjusted estimated marginal means with 95% confidence intervals 
(error bars). P value indicates the between-group (exercise vs. control) comparison of change 
(unpaired; group × time interaction) in a linear mixed-effects model with a random intercept 
and age, sex, group, and time as fixed effects. 
C: Baseline and 6-month data for CVNN. 
Data are age- and sex-adjusted estimated marginal means with standard error (error bars). P 
values reflect the within-group change over time (paired; baseline vs. 6-months). 
D: Change in CVNN from baseline. 
Data are age- and sex-adjusted estimated marginal means with 95% confidence intervals 
(error bars). P value indicates the between-group (exercise vs. control) comparison of change 
(unpaired; group × time interaction) in a linear mixed-effects model with a random intercept 
and age, sex, group, and time as fixed effects. 
CVNN, coefficient of variation of normal RR intervals; VO2peak, peak exercise oxygen 
uptake. 
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Highlights 
- A study of exercise for type 2 diabetes-related subclinical diastolic dysfunction. 
- Exercise capacity improved by ~11% over 6 months vs. −1% in controls. 
- Cardiac sympathovagal balance improved; other autonomic function data were mixed. 
- The primary heart-rate variability endpoint did not significantly change. 
- Possible anti-fibrotic effects did not extend to myocardial functional adaptations. 
